A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of TROP2-Directed Antibody-Drug Conjugate LCB84, as a Single Agent and in Combination With an Anti-PD-1 Ab, in Patients With Advanced Solid Tumors November 7, 2023
First-in-Human Study of STX-478, a Mutant-Selective PI3Kα Inhibitor as Monotherapy and in Combination with Other Antineoplastic Agents in Participants with Advanced Solid Tumor November 7, 2023
A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the DNA Polymerase Theta Inhibitor ART6043 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors November 7, 2023
A First-in-human, Multicenter, Open-label, Dose Escalation and Dose Expansion Phase 1 Study in Patients with Advanced Solid Tumors to Evaluate the Safety of Intravenously Administered ALG.APV-527 November 7, 2023
A First-in-Human, Open-Label, Multi-Center Phase 1 Study of TST003 in Subjects with Locally Advanced or Metastatic Solid Tumors November 7, 2023
A Phase 1/2a, Open-Label, Safety, Pharmacokinetic, and Preliminary Efficacy Trial of Oral ATRN-119 in Patients with Advanced Solid Tumors November 7, 2023
Phase 1/2 Study of PRO1184 in Patients With Locally Advanced and/or Metastatic Solid Tumors November 7, 2023
A Phase 1/2 Multicenter, Open-label, Dose-escalation, Safety, Pharmacodynamic, and Pharmacokinetic Study of Q901 Administered via Intravenous Infusion in Adult Patients with Selected Advanced Solid Tumors with a Cohort Expansion at the Recommended Phase 2 Dose November 7, 2023
A Phase 1, Open-Label, Multicenter, Dose Escalation Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of IMM2902 in Patients with HER2-Expressing Advanced Solid Tumors November 7, 2023
A Phase 1, Open-Label Study of ABSK061 to Assess Safety, Tolerability, and Pharmacokinetics in Patients with Advanced Solid Tumors November 7, 2023